LEVEL 03 — THE NUMBERS
Thymulin Dosage in the Research Literature
What was administered, to which species, by which route — reported as study findings, never as a protocol to follow.
Read this first
This page reports thymulin dosage exactly as it appears in studies — what researchers gave to animals and cells, in what amounts, by what method. The doses are tiny: nanograms to a few micrograms per animal, not the milligram amounts people associate with everyday medicines. None of this is a human dose or a schedule to follow. Thymulin is not FDA-approved, there is no established human dosing, and its activity depends entirely on zinc being present (a strict on/off cofactor). Treat everything below as a record of experiments, not instructions.
Thymulin Dosage in the Research Literature
Reported research doses span from nanograms to low micrograms per animal, depending on the model and route [4][13]. In rodent anti-inflammatory and analgesia work, doses fall in the nanogram-to-low-microgram range per animal — for example, roughly 0.1-1 microgram given intracerebroventricularly (into the brain's fluid spaces) and roughly 1-1000 ng given intraperitoneally [4][14]. In a virus-protection model, mice received serum thymic factor at 10-50 microgram before challenge, by subcutaneous injection [10]. In a radioprotection study, mice received 3-100 microgram/day by daily subcutaneous injection [15].
A recurring caveat applies: these are doses in specified species, optimized for an experimental endpoint, not protocols for human use. The numbers are study findings.
What doses of thymulin were used in studies?
Studies used nanogram-to-microgram amounts per animal. Examples include 10 ng/100g and 50 ng/100g body weight in chickens [13], 10-50 microgram subcutaneously in mice [10], and 3-100 microgram/day subcutaneously in mice [15]. These are species-specific research doses, reported as findings.
What doses of thymulin were used in animal studies?
Reported research doses range from nanograms to low micrograms per animal — for instance, roughly 0.1-1 microgram intracerebroventricularly and 1-1000 ng intraperitoneally in rodents [4][14], and 10-50 microgram subcutaneously in mice for virus protection [10]. These are study findings in specified species, not human protocols.
Routes used in thymulin research
Thymulin and its gene-therapy vectors have been delivered by many routes in research, each chosen to fit the model. Reported routes include intraperitoneal, subcutaneous, intracerebroventricular, intratracheal (for inhaled gene therapy), and intramuscular for vector delivery, plus in-vitro incubation with cultured cells [4][7][8]. A topical zinc-thymulin formulation was also explored in a small cosmetic pilot [4].
How is thymulin administered in research?
Studies have used intraperitoneal, subcutaneous, intracerebroventricular, intratracheal (gene therapy), intramuscular (vector), and in-vitro routes in animals and cells [4][7][8]. These are experimental routes in research models, not human administration guidance. The route is matched to the question being asked — brain delivery for CNS analgesia, inhaled delivery for asthma gene therapy, in-vitro incubation for lymphocyte studies.
What is known about thymulin's half-life
Native thymulin is a small peptide, and small peptides clear quickly from circulation. The honest answer on thymulin half life is that its precise human pharmacokinetic half-life is not well established in the public literature [4]. What the literature does tell you is indirect but informative: researchers developed gene-therapy approaches — adenoviral and nanoparticle vectors that make cells produce thymulin continuously — specifically because sustaining circulating levels of the native peptide is difficult [4][7]. The asthma study, for instance, used a single intratracheal dose of a thymulin-expressing plasmid precisely to achieve durable expression rather than a fleeting peptide pulse [7].
What is known about thymulin's half-life?
Thymulin is a small peptide with a short circulating half-life, and its precise human pharmacokinetic half-life is not well characterized in the public literature [4]. The development of gene-therapy delivery to sustain circulating thymulin is itself evidence that the native peptide does not persist long on its own [4][7].
Why zinc complicates every dose
There is a structural reason thymulin dosing resists a clean number: the peptide is only active when zinc-bound, so its effect depends on the zinc available to saturate it [1][9]. Zinc chelation abolishes activity, and the zinc-free apo-peptide is inactive until zinc is restored [1]. In deep zinc deficiency, low thymulin levels reflected reduced peripheral zinc saturation of the peptide rather than a shortage of the peptide itself [9]. This is why aging research often studies zinc repletion alongside, or instead of, thymulin [9][12]. A dose of peptide without adequate zinc is a dose of the inactive form. The mechanism is detailed on the zinc-dependence of thymulin page; the aging context is on thymulin, zinc status, and immune aging.